Wondering if Regeneron Pharmaceuticals is a hidden gem or just fairly priced? You are not alone; investors everywhere are ...

REGN stock is presently trading nearly 38% lower than its 1-year peak, and is also being traded at a P/S multiple that is ...

Return on Assets (ROA): Regeneron Pharmaceuticals's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 3.67%, the company showcases ...

Discover why Regeneron Pharmaceuticals, Inc.'s Q3 earnings impress, fueled by Dupixent growth and a robust pipeline. Click ...

Regeneron posts Q3 earnings of $11.83 per share, topping estimates as Dupixent profits lift results despite weaker Eylea ...

Regeneron Pharmaceuticals (REGN) is forecasting annual earnings growth of 7.41%, with revenue also projected to rise by 7% ...

Across its portfolio, Regeneron brought in $3.75 billion in sales and adjusted earnings of $11.83 a share. Sales edged 1% ...

While the company is making efforts to diversify its revenue base and develop its oncology franchise, Eylea’s dismal performance in an increasingly competitive environment has dampened investors’ ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds. On August 4, BMO Capital lifted the price target on the company’s stock ...

Dupixent shows stable positive dynamics and becomes the main asset, while sales of Eylea are under pressure. Regeneron still has a strong pipeline, but the focus is shifting toward oncology. Valuation ...

Investors in Regeneron Pharmaceuticals, Inc. (Symbol: REGN) saw new options become available today, for the September 5th expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...

Fintel reports that on October 29, 2025, Guggenheim maintained coverage of Regeneron Pharmaceuticals (NasdaqGS:REGN) with a ...